Skip to content
  • English
  • Business
  • Entertainment
  • National
  • Lifestyle
  • Education
Daily News India

Daily News India

Just another WordPress site

  • English
  • Business
  • Entertainment
  • National
  • Lifestyle
  • Education
  • Toggle search form
  • Co-living apartments- The emerging trend of 2023 Business
  • Flipkart Elevates Ankit Agarwal to Vice President, Business Finance Business
  • Toyam Industries Ltd. unites with MX player to launch the first MMA reality TV show Business
  • Tanaji Bhimaji Gargote Crowned IRG Champion at South Asia’s First Mind Sports Championship’s West Zone Finals Press Release
  • How Construction ERP is Revolutionizing Project Management Business
  • Psoriasis and Skin Diseases – The Ayurvedic Approach at Kalpataru Ayurvediya Chikitsalaya Health
  • EarlyJobs Expands with New Franchise in Rampur, Strengthening Recruitment Network Across West UP Press Release
  • Kretto Syscon to announce Q4 results on April 24, continues to attract strong investor interest Business

Sotac Pharmaceuticals Ltd brings its IPO on 28th March, To be listed on NSE Emerge Platform

Posted on March 28, 2023 By

Ahmedabad (Gujarat) [India], March 28: Ahmedabad based Sotac Pharmaceuticals Ltd. specializes in the production of high-quality pharmaceutical products on a loan license or contract manufacturing basis. The company has announced its IPO for 30,00,000 shares, where the price band per equity share will be Rs 105 to Rs 111, with each equity share bearing a face value of Rs 10. The shares will be sold in lot size of 1200 shares. Out of the 30,00,000 shares, 14,23,200 shares will be reserved for the QIB quota (including Anchor Reservation), 4,28,400 shares will be reserved for HNI quota, 9,98,400 shares will be reserved for the retail quota and 1,50,000 shares will be reserved under the market maker quota. The issue opens on the 28th March for the Anchor and on the 29th March for the public. The issue closes on the 3rd April, 2023. It will subsequently be listed on the NSE Emerge platform. Beeline Capital Advisors Pvt. Ltd. is the lead manager to the issue and KFin Technologies Ltd. is the registrar to the issue.

The issue proceeds will be utilised for the following:

  • To meet working capital requirements
  • Investment in subsidiary
  • Upgradation/Construction of existing/new building in the existing premises
  • General corporate purpose
  • Issue expenses

Sotac Pharmaceuticals has a diverse product portfolio that includes a wide range of pharmaceuticals, nutraceuticals, and food products. Their state-of-the-art manufacturing facility enables them to produce high-quality products, including tablets, capsules, oral liquids, dry syrups, and external preparations such as ointments, lotions, and creams. The manufacturing unit I is located in Sanand GIDC-Il, Ahmedabad district. The facility features a comprehensive production unit, quality control department, microbiological laboratory, and storage for raw materials and finished products has been approved by the World Health Organization’s Good Manufacturing Practices (WHO GMP) standards. The manufacturing unit II is also located in Sanand GIDC-Il, Ahmedabad district for Beta Lactam products has been approved by the World Health Organization’s Good Manufacturing Practices (WHO GMP) standards. The manufacturing plant operates at the highest safety and environmental standards, ensuring the necessary isolation and differentiation of processes and sections to minimize the chances of cross-contamination. Its impressive client list includes Cadila Pharmaceuticals, Intas, Ronak Health Care, Sunrest Lifesciences, Lincoln Pharmaceuticals, Treatwell Pharma and many more. The company’s products have a pan India and global presence.

The Company has recently completed capacity expansion and has an upcoming facility in its subsidiary, Sotac Lifesciences Private Limited, providing significant room for growth. Utilization of existing unutilized capacities is expected to improve return ratios. The company has well equipped R&D capabilities, in wholly owned subsidiary Sotac Research Private Limited. The company’s progress is backed by its experienced promoters of diverse backgrounds with a combined experience of over 59 years in various industries. Their leadership, guidance and strategic oversight play a pivotal role in driving the company’s success and growth.

Sotac Pharmaceuticals has recorded impressive financial growth over the years. Its consolidated revenue from operations for 6MFY23 was Rs 39.75 crores, while it was Rs 73.15 crores for FY22 and Rs 48.84 crores for FY21. Its consolidated EBITDA for 6MFY23 was Rs 3.68 crores, while it was Rs 6.14 crores for FY22 and Rs 1.46 crores for FY21. The company registered a consolidated PAT of Rs 0.47 crores for 6MFY23, which was Rs 2.88 crores for FY22.

The promoters of the company are Mr Sharadkumar Dashrathbhai Patel, Mr Dineshkumar Babulal Gelot, Mr Vishalkumar Devrajbhai Patel, Mr Chetankumar Bachubhai Patel and Mrs Kiran Baldevbhai Jotania.

If you have any objection to this press release content, kindly contact pr.error.rectification@gmail.com to notify us. We will respond and rectify the situation in the next 24 hours.

Business Tags:Business

Post navigation

Previous Post: Infinium Pharmachem Limited announces its IPO for 31st March 2023, To be listed on NSE Emerge
Next Post: Asian Brand and Leadership Conclave by THE BRAND STORY Concludes Successfully In Dubai

Related Posts

  • Blue Cloud Announces October Service Acceptance by SpaceX International Ltd, Labuan; US$10 Million Invoiced under Existing US$150 Million Programme Business
  • This AI Startup Is Turning India’s Hiring Chaos into Quick Commerce Business
  • From SME to Mainstage: Inside Bright Outdoor’s High-Yield Pivot to DOOH and Transit Media Business
  • Fabtech Technologies Cleanrooms Limited Expands into UAE with New Subsidiary for Partition Manufacturing Business
  • Launch Of Sustainable Fashion Brand – Lifoholic: Incredibly Indian Business
  • Why To Invest In Diamonds Business

Recent Posts

  • Fredna Dental Systems Partners with South Korea’s & Introduces BIOTEM AR Implant Technology in India
  • Make Your Financial Plans Easier with a Personal Loan
  • Gohil Group plans G-Farm retail outlets in Ahmedabad and Surat
  • P.C. Chandra Group’s 13th Edition of Jahar Lal Chandra Merit Scholarship Programme
  • Quest Alliance CEO Aakash Sethi Named to TIME100 Next: India, TIME’s Inaugural List of 100 Individuals Defining the Future of India

Recent Comments

  • Unknown on Participants Reap Rewards in Wellman’s 8-Week Digital Campaign: IPL Tickets, Autographed Virat Kohli Merchandise, and More!
  • Sabr Associates LLP, Gujarat goes global with Make in India exports Business
  • The Inspiring Story of Cyber Security Auditor & Entrepreneur, Deepak Kumar Nath, Founder, Threatsys Business
  • Equator’s New Year Sale: Upto 40 percent off* on Home Appliances Business
  • World Aplastic Anemia Day- Anemia Rath flagged off in Indore on the part of the anaemia awareness campaign Press Release
  • The Manatomy Develops AI System to Personalize How Men See Fashion and Let  Users See Themselves in Personalized Outfits Business
  • IPS Academy Student Bags Top Spot in Speech Contest, Set to Shine at International Management Conclave Lifestyle
  • Fybros Takes a Stand Against Plastic Pollution on World Environment Day Lifestyle
  • Captain Indira Vashist Carena is set to embark on initiatives to empower girls to pursue their education Lifestyle

Copyright © 2026 Daily News India.

Powered by PressBook News WordPress theme